Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Novo Nordisk A/S Common Stock (NY:NVO)

49.11 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
99 100 Next >
LifeMD Stock Plummets 40%. Why Weight Loss Isn't Just A Gimme.
The company is struggling with several headwinds as it works to develop its obesity plan. 
Via Investor's Business Daily
Why Is Everyone Talking About Novo Nordisk Stock?
Competition is hurting sales of critical products. 
Via The Motley Fool
Novo Nordisk Slumps As It Cautions 'Unsafe And Unlawful' Knockoffs Will Pressure Wegovy
The company says it's working to ensure patients only receive semaglutide produced by Novo Nordisk. 
Via Investor's Business Daily
Topics Earnings
Shareholders of Novo Nordisk A/S Should Contact Levi & Korsinsky Before September 30, 2025 to Discuss Your Rights - NVO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Shareholders of Novo Nordisk A/S Should Contact Levi &amp; Korsinsky Before September 30, 2025 to Discuss Your Rights - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
Earnings Scheduled For August 6, 2025
 
Via Benzinga
A Rough Day for "Dividend Knights"
Between battered industries and overlooked opportunities, plenty of dividend-paying companies have slipped. 
Via The Motley Fool
Compounded GLP-1s And Competition Force Novo Nordisk To Slash Outlook
Novo Nordisk reported Q2 sales of $11.7 billion, missing consensus. Sales increased by 13% in Danish kroner, driven by GLP-1 diabetes and obesity care sales. 
Via Benzinga
Bryan Johnson Spent Millions To Be 18 Again—Says Novo Nordisk's Ozempic Anti-Aging Hype Is Misleading: 'Data Is Not There'
Tech entrepreneur Bryan Johnson refutes claims that Novo Nordisk AS's Ozempic demonstrates anti-aging properties. 
Via Benzinga
Novo Nordisk Edges Up Premarket As Q2 Wegovy Sales Defy Copycat Threats: Retail Stays Bullish Amid Tariff Pressure
The results follow Novo’s worst weekly decline in its history after the company slashed its full-year guidance. 
Via Stocktwits
Topics Government World Trade
Investor Alert: Robbins LLP Informs Investors of the Novo Nordisk A/S Class Action Lawsuit
From Robbins LLP
Via GlobeNewswire
US Market Under Pressure: Amazon, Eastman Chemical, and Hims & Hers Among Top Losers
The U.S. stock market experienced a turbulent start to August 2025, marked by significant declines for several prominent companies. This downturn, following a volatile end to July, has left investors... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Rosen Law Firm Urges Novo Nordisk A/S (NYSE: NVO) Investors with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
Why Novo Nordisk Stock Is Down Again Today
Are you brave enough to catch this falling knife? 
Via The Motley Fool
What's Going On With Novo Nordisk Stock?
Management pointed to competitors gaining market share in key product categories. 
Via The Motley Fool
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
From Pomerantz LLP
Via GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
From Faruqi & Faruqi LLP
Via GlobeNewswire
Novo Nordisk Downgraded By UBS Over Uncertain Outlook For Wegovy, But Retail Prefers To Look At The Sunny Side
UBS downgraded Novo Nordisk to ‘Neutral’ from ‘Buy’ with a price target of DKK 340, down from DKK 600. 
Via Stocktwits
Inspire Medical Systems Crashes 32% As Eli Lilly's GLP-1 Weighs On Guidance
The company makes implantable devices for sleep apnea, an area Eli Lilly is marketing its weight-loss drug. 
Via Investor's Business Daily
Levi &amp; Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 30, 2025 - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
Levi & Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 30, 2025 - NVO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
This Block Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
 
Via Benzinga
Novo Nordisk Stock Sinks—But Is a Bottom Finally In?
Novo Nordisk stock is down over 43% in 2025 as investors weigh weak guidance, GLP-1 competition, and the potential for a rebound after earnings 
Via MarketBeat
EXCLUSIVE: Vivani Prioritizes Semaglutide-Based Implant After Promising Preclinical Data
Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data showing 231-day weight loss from a single dose. 
Via Benzinga
Dollar's Worst Start Since 1970s Could Dent European Corporate Profits
 
Via Benzinga
Massive News for Novo Nordisk Stock Investors!
Management told investors to expect slower sales and profit growth in 2025. 
Via The Motley Fool
Hims & Hers Health Stock Plunges Over 13% In Tuesday Pre-Market: What's Going On?
Hims & Hers Health Inc. (NYSE: HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported second-quarter revenue on Monday that missed Wall Street expectations. 
Via Benzinga
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO): A High-Quality Dividend Stock with Strong Growth and Stability
NVO offers dividend investors a strong 3.62% yield, 16.56% growth, and high profitability, backed by solid financial health and growth potential. 
Via Chartmill
NOVO NORDISK A/S (NYSE: NVO) INVESTOR ALERT – Investors With Large Losses in Novo Nordisk A/S Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
IBD 50's Hims & Hers Plummets 9% On Second-Quarter Sales Miss
The company reiterated its sales outlook for the year, despite coming in with lighter-than-expected second-quarter sales. 
Via Investor's Business Daily
Topics ETFs Earnings
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.